Marie L. Gibson
Marie L. Gibson concentrates primarily on mergers and acquisitions and general corporate matters.

Bio

Ms. Gibson has represented acquirers, targets and financial advisors in U.S. and international mergers and acquisitions, including public and private transactions as well as negotiated and contested acquisitions. Her experience includes proxy contests, corporate governance advice, work with distressed businesses and other general corporate matters. Although her practice is broad-based, she has extensive experience in the health care and energy industries. Ms. Gibson has been named Woman Dealmaker of the Year by The M&A Advisor and was named as a Finance & Transactional Star in LMG Life Sciences’ 2016 rankings.

Significant representations include:

  • Rite Aid Corporation in its pending sale of stores for $5.175 billion to Walgreens Boots Alliance, following the termination of a planned merger between the parties;
  • Moody’s Corporation in its €3 billion acquisition of information services provider Bureau van Dijk, headquartered in Amsterdam;
  • Intrawest Resorts Holdings in its $1.5 billion sale to a new entity formed by Aspen Skiing Co. and KSL Capital Partners;
  • Anheuser-Busch InBev in its $20.1 billion acquisition of the remaining stake of Grupo Modelo, S.A.B. de C.V. not previously owned by it;
  • DigitalGlobe, Inc., a provider of earth imagery and geospatial information solutions, in its $900 million merger with GeoEye, Inc., an information technology provider for the aerospace and defense industry;
  • Valeant Pharmaceuticals International, Inc. in multiple acquisitions and licensing agreements, including its $8.7 billion merger with Bausch & Lomb; its $1 billion acquisition of Sprout Pharmaceuticals; its acquistion of the largest Egyptian pharmaceutical company, Amoun Pharmaceuticals; its acquisition of Synergetics, Inc.; its $440 million acquisition of Obagi Medical Products; its $312 million acquisition of OraPharma from Water Street Healthcare Partners, LLC; its $425 million acquisition of Dermik, a developer of dermatological products, from sanofi-aventis; the $345 million acquisition of Ortho Dermatologics from Janssen Pharmaceuticals, Inc., an affiliate of Johnson & Johnson; its acquisition of the North American rights to Elidel® and Xerese™ from Meda AB; and the $300 million acquisition of the U.S. and Canadian rights to Zovirax® from GlaxoSmithKline plc;
  • Collagen Matrix Inc., a manufacturer of collagen- and mineral-based extracellular matrices for tissue and organ repair and regeneration, in its sale to Metalmark Capital LLC, a private equity firm;
  • Mylan Inc. in a variety of matters, including its $1.6 billion acquisition of the Agila injectables businesses from Indian pharmaceutical company, Strides Arcolab Limited; its acquisition of India-based Matrix Laboratories Ltd.; its attempted acquisition of King Pharmaceuticals; and its defense against an unsolicited offer by Carl Icahn to acquire Mylan and in a related proxy fight;
  • Greenhill & Co., Inc. in its acquisition of Cogent Advisors;
  • Castle Harlan, Inc., a private equity firm, in its acquisition of Securus Technologies, Inc. from H.I.G. Capital, LLC, as well as in its acquisition of IDQ Holdings, Inc. from Arsenal Capital Partners;
  • Carnegie Hall in a variety of corporate matters;
  • MDS Inc. in the $650 million sale of its analytical technologies business to Danaher Corporation;
  • Delphi Corporation in a variety of corporate matters relating to its Chapter 11 case, including the stalking horse bid that eventually led to its exit from bankruptcy;
  • Fairfield Greenwich Group in a variety of matters, including the transfer of its fund of funds business to Sciens Capital Management, LLC;
  • Anheuser-Busch Companies, Inc. in its $52 billion acquisition by InBev N.V. (Brazil-Belgium). This deal was named “U.S. M&A Deal of the Year” for 2008 at the Financial Times and mergermarket M&A Awards Americas (October 30, 2008);
  • Bentley Pharmaceuticals, Inc. in its $360 million sale to Teva Pharmaceutical Industries Limited and the related spin-off of CPEX Pharmaceuticals, Inc.; and
  • VISX, Incorporated in its successful proxy contests with Carl Icahn.

Ms. Gibson has represented numerous companies in the energy sector, including:

  • TECO Energy in its pending sale to Emera in a deal valued at $10.4 billion;
  • CMS Energy Corporation in the sale of its ownership interests in businesses in the Middle East, Africa and India to the Abu Dhabi National Energy Company; and the sale of its natural gas gathering and processing field services business to a Morgan Stanley Capital Partners portfolio company;
  • New England Electric Systems in its merger with National Grid Group plc and its acquisition of Eastern Utility Associates; and
  • National Grid in its acquisition of KeySpan Corporation.

Ms. Gibson actively is involved in Skadden’s training, summer associate and pro bono programs. She earned a Certified Public Accountant license and practiced as an auditor at Price Waterhouse prior to attending law school. She is currently serving as visiting clinical lecturer in law at Yale Law School.

Credentials

Education

  • J.D., Fordham University School of Law, 1996 (Order of the Coif)
  • M.B.A. and B.B.A., Pace University (combined degree program), 1991

Admissions

  • New York

Marie L. Gibson

Partner, Mergers and Acquisitions
marie.gibson@skadden.com